Khurram Nawaz, M.Sc.
Karen Pomeranz, M.Sc., Ph.D.
Michael Hughes, M.Sc., Ph.D.
Benjamin Guikema, Ph.D.
Acute myeloid leukemia (AML) is a biologically heterogeneous
group of malignancies of the bone marrow that predominantly affect adult
patients aged 60 or older. Although recent advances in the molecular understanding
of AML have led to refinements in the classification and prognostication of
patients, treatment options have remained virtually unchanged, and all AML
subtypes (except acute promyelocytic leukemia [APL]) are treated with the same
chemotherapeutic regimens. Current treatment of elderly AML patients is particularly
challenging because a substantial proportion of these patients are not eligible
for standard intensive chemotherapy or hematopoietic stem-cell
transplantation—highlighting the crucial need for efficacious therapies that
are less toxic than current myeloablative chemotherapy regimens.
Questions Answered in This Report:
Several emerging therapies, including targeted agents, are in clinical
development for elderly patients with AML. Which of these agents are most
likely to launch? What are interviewed experts’ opinions of emerging therapies?
How rapidly will physicians add these new treatments to their armamentarium?
The hypomethylating agent Dacogen (Eisai/Johnson &
Johnson/Astex Pharmaceuticals’ decitabine) earned European approval in
September 2012 for the treatment of elderly patients with AML who are not
eligible for standard induction chemotherapy. What is the role of
hypomethylating agents in the current treatment of AML? What are thought
leaders’ perceptions of Dacogen? Does European approval of Dacogen affect
physicians’ perceptions of the hypomethylating agent Vidaza (Celgene’s
Interviewed experts state that there is a great need for
efficacious therapies to treat relapsed/refractory (R/R) AML. Can any of the
emerging drugs be used in this patient population? What are interviewed
experts’ opinions of emerging therapies for R/R AML? What challenges and
Markets covered: United States, France, Germany, Italy,
Spain, and United Kingdom.
Primary research: Eight country-specific interviews with
expert hematological oncologists.
Epidemiology: Diagnosed incidence of AML, diagnosed
incidence of APL.
Population segments: First-line AML, relapsed/refractory
AML, first-line APL, relapsed/refractory APL.
Emerging therapies: Phase II: 13 drugs; Phase III: 5 drugs.